Although the targeting of ERβ as a therapy for various cancers including Breast cancer has been conceptualized over the last couple of decades, since ERβ1 has been acknowledged as a tumor suppressor, but the focus has always been on developing an agonist to activate its function [55]. Here, ESR2 is linked to breast carcinoma.